AbbVie's Marketing Of AndroGel 'Insidious,' Jury Told
By Diana Novak Jones ( October 3, 2017, 8:54 PM EDT) -- Attorneys for a man who had a heart attack while using AbbVie Inc.'s testosterone replacement therapy drug AndroGel told an Illinois federal jury Tuesday the company's efforts to expand the drug's market without studying its risks were part of an "insidious" plan to up its profits....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.